Suitability of 11C-ORM-13070 as a PET Tracer

Orion Pharma

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: 11C-ORM-13070

Study type: Interventional

Funder types: Industry

Identifiers

NCT00735774

3099001

Details and patient eligibility

About

The purpose of the study is to evaluate the suitability of 11C-ORM-13070 as a positron emission tomography tracer.

Enrollment: 18 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Good general health ascertained by detailed medical history and physical examination
• Males between 18 and 45 years
• Body mass index (BMI) between 18-30 kg/m2
• Weight 55-95 kg (inclusive)

Exclusion criteria

• Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator
• Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant medication during the study.
• Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol)
• Current use of nicotine-containing products more than 5 cigarettes or equivalent/day
• Inability to refrain from using nicotine-containing products during the stay in the study centre
• Inability to refrain from consuming caffeine-containing beverages during the stay in the study centre e.g. propensity in getting headache when refraining from caffeine-containing beverages
• Blood donation or loss of significant amount of blood within 3 months prior to the screening visit
• Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance
• Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part into the study
• Anatomical abnormality in MRI which may in the opinion of the investigator interfere with the interpretation of PET results
• Participation in a drug study within 3 months prior to the entry into this study
• Participation in a prior PET study

Trial design

18 participants in 1 patient group

11C-ORM-13070

Experimental group

Treatment:

Drug: 11C-ORM-13070